HRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Heron Therapeutics Inc (HRTX) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators, options data, and financial performance suggest a lack of strong positive momentum or catalysts. The stock's recent price movement is modest, and there are no significant news or insider activities to support a bullish case. Given the negative financial trends and absence of clear trading signals, it is better to hold off on investing in this stock right now.
The technical indicators show a bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 42.239, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.846, with resistance at 0.926 and support at 0.766. Overall, the technicals do not indicate a strong buy signal.
NULL. There are no recent news, insider activities, or significant events to act as positive catalysts for the stock.
The company's financial performance in Q4 2025 shows significant declines in revenue (-0.47% YoY), net income (-180.64% YoY), EPS (-200.00% YoY), and gross margin (-3.08% YoY). These negative trends weigh heavily on the stock's outlook.
In Q4 2025, Heron Therapeutics reported a revenue drop to $40.59M (-0.47% YoY), net income dropped to -$2.95M (-180.64% YoY), and EPS dropped to -0.02 (-200.00% YoY). Gross margin also declined to 72.61% (-3.08% YoY). Overall, the financial performance is weak and does not support a buy recommendation.
No recent analyst rating or price target changes are available for HRTX. This lack of data makes it difficult to gauge Wall Street sentiment on the stock.
